Drawing for S

USPTO serial 90086260

S

Reviewed by CopyMark Law Group

Filing date
Status date
Registration date
—
Examiner
HELFMAN, JUDITH MICHELLE
Law office
TTAB

What this means

These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances. If abandonment was unintentional, consult counsel about a petition to revive. Otherwise file a new application if protection is still needed.

Status 604: These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances.

Need help with S?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

MONICA RIVA TALLEY

MONICA RIVA TALLEY STERNE KESSLER GOLDSTEIN & FOX PLLC1100 NEW YORK AVENUE NWWASHINGTON, DC 20005UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
005Antibiotics; Collyrium; Chemical preparations for pharmaceutical or medical purposes, namely, for the treatment of infectious diseases, immune system related diseases and disorders, respiratory diseases, allergy, pain, digestive system diseases, urinary system diseases, cardiovascular and cerebrovascular diseases, tumors, blood diseases, gynecological diseases, hyperproliferative disease, blood vessel disease, skin disease, obesity, chronic pain and endocrine disease; Pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, cognitive disorders, digestive system diseases, urinary system diseases, cardiovascular and cerebrovascular diseases, tumors, blood diseases, gynecological diseases, hyperproliferative disease, blood vessel disease, skin disease, obesity, chronic pain and endocrine disease; Pharmaceutical preparations for the treatment of infectious diseases, immune system related diseases and disorders, respiratory diseases, allergy, pain, digestive system diseases, urinary system diseases, cardiovascular and cerebrovascular diseases, tumors, blood diseases, gynecological diseases, hyperproliferative disease, blood vessel disease, skin disease, obesity, chronic pain and endocrine disease; Biological preparations for the treatment of infectious diseases, immune system related diseases and disorders, respiratory diseases, allergy, pain, digestive system diseases, urinary system diseases, cardiovascular and cerebrovascular diseases, tumors, blood diseases, gynecological diseases, hyperproliferative disease, blood vessel disease, skin disease, obesity, chronic pain and endocrine disease; Prescription and non-prescription medicines, namely, injectable pharmaceuticals, pills, tablets, capsules, caplets, liquid drops, sachets, spray, ointment, cream, gel, lotion, patch, inhaler, granule, film, suspension, infusion, suppository and pharmaceutical preparations for the treatment of infectious diseases, immune system related diseases and disorders, respiratory diseases, allergy, pain, digestive system diseases, urinary system diseases, cardiovascular and cerebrovascular diseases, tumors, blood diseases, gynecological diseases, hyperproliferative disease, blood vessel disease, skin disease, obesity, chronic pain and endocrine disease; Drug delivery agents in the form of powders, tablets, capsules, injectable pharmaceuticals, pills, caplets, liquid drops, sachets, spray, ointment, cream, gel, lotion, patch, inhaler, granule, film, suspension, infusion and suppository that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; Diagnostic preparations for veterinary purposes; Veterinary preparations, namely, pain relief medication, anti-infective medication, immune disease medication, respiratory disease medication, allergy and pain related medication, digestive system medication, urinary system medication, cardiovascular and cerebrovascular medication, tumor medication, blood disease medication, hyperproliferative disease medication, blood vessel disease medication, skin disease medication, obesity medication, chronic pain medication and endocrine disease medicationABANDONED—
035Demonstration of goods; Advertising services; online advertising on a computer network; Business management and organization consultancy; Business management consultancy; Business investigations; Professional business consultancy; Import-export agency services; Publication of publicity texts; Commercial information agency services; Market analysis; providing commercial information and advice for consumers in the choice of products and services; Provision of an online marketplace for buyers and sellers of goods and services; Organizing exhibitions for technology for business purposes; Wholesale store services for pharmaceutical, veterinary and sanitary preparations and medical supplies; Retail store services for pharmaceutical, veterinary and sanitary preparations and medical suppliesABANDONED—
042Research and development of new products for others; Scientific research; Chemical analysis; Chemical research; Biological research; Cosmetic research; Medical research; Development of pharmaceutical preparations and medicines; Conducting clinical trials for others, being scientific research; Inspection of medical equipment for quality control purposes; Chemical engineering; Technology consultation in the field of medical research; Research and development of technology in the field of medical researchABANDONED—
044Pharmaceutical advice; Health counselling; Beauty salon services; Medical analysis services for diagnostic and treatment purposes provided by medical laboratories; Alternative medicine services; Food nutrition consultancy; Health care; Nursing, medical; Medical and pharmaceutical consultation; Telemedicine services; Pharmacists' services to make up prescriptions; Nutritional therapy services; Veterinary services, namely, veterinary assistance; Hygienic and beauty care; Charitable services, namely, providing medical services to underdeveloped countries; Charitable services, namely, providing medical equipment and services to underserved communitiesABANDONED—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Apr 17, 2023MAB4ABANDONMENT NOTICE E-MAILED - INTER PARTES DECISION—
Apr 17, 2023ABN4ABANDONMENT - AFTER INTER PARTES DECISION—
Apr 17, 2023OP.TOPPOSITION TERMINATED NO. 999999—
Apr 17, 2023OP.DOPPOSITION DISMISSED NO. 999999—
May 17, 2021OP.IOPPOSITION INSTITUTED NO. 999999—
Feb 18, 2021ETOFEXTENSION OF TIME TO OPPOSE RECEIVED—
Jan 19, 2021NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Jan 19, 2021PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Dec 30, 2020NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Dec 14, 2020CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Dec 14, 2020XAECEXAMINER'S AMENDMENT ENTERED—
Dec 14, 2020GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Dec 14, 2020GNEAEXAMINERS AMENDMENT E-MAILED—
Dec 14, 2020CNEAEXAMINERS AMENDMENT -WRITTEN—
Dec 14, 2020ZZZXPREVIOUS ALLOWANCE COUNT WITHDRAWN—
Dec 8, 2020PBCRWITHDRAWN FROM PUB - OG REVIEW QUERY—
Nov 23, 2020CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Nov 23, 2020XAECEXAMINER'S AMENDMENT ENTERED—
Nov 23, 2020GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Nov 23, 2020GNEAEXAMINERS AMENDMENT E-MAILED—
Nov 23, 2020CNEAEXAMINERS AMENDMENT -WRITTEN—
Nov 19, 2020DOCKASSIGNED TO EXAMINER—
Sep 2, 2020MDSCNOTICE OF DESIGN SEARCH CODE E-MAILED—
Sep 1, 2020NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Aug 4, 2020NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance